Cairn Surgical Unveils Innovative Locator for Breast Cancer Surgery
Cairn Surgical, Inc., a leader in medical technology, has reached an important milestone in breast cancer surgery with the first commercial use of its unique Breast Cancer Locator (BCL™) System. This cutting-edge device is poised to change breast-conserving surgery, offering greater precision and effectiveness for patients facing breast cancer.
Successful First Use of the BCL System
In a recent procedure, Prof. Dr. med. Hisham Fansa, who heads the Breast Center and plastic surgery department at a prominent Swiss hospital, successfully deployed the BCL System. This technology has been carefully crafted to help surgeons pinpoint tumor details—like shape, size, and location—thereby ensuring clearer margins during lumpectomy operations.
Encouraging Initial Results
Prof. Dr. Fansa shared his excitement about this launch, highlighting how impactful this technology can be for achieving excellent surgical outcomes. "In our first commercial case, we observed a negative margin, which signifies the complete removal of detectable cancer," he noted. This brings hope for improved surgical results and lessens the chances of patients needing follow-up surgeries.
Importance of the BCL System
The BCL System is specifically designed to reduce positive margin rates while improving the efficiency of breast-conserving surgeries. It includes a specialized supine MRI that captures the breast in a surgical position, which is then turned into a 3D-printed model that accurately reflects the patient's breast contours. This model becomes an essential tool during surgery, enabling surgeons to accurately locate and remove tumors.
Enhanced Surgical Approaches
When performing surgeries, healthcare professionals utilize the BCL alongside a real-time interactive 3D image known as the Visualizer. This combination provides crucial data throughout the tumor removal process, making the surgical experience more reliable than ever. By using this state-of-the-art technology, surgeons can significantly minimize risks and enhance patient outcomes.
Clinical Trials and Future Prospects
Cairn Surgical is also dedicated to sharing clinical data from a multicenter European post-market study that includes 33 patients in the near future. Previous studies have shown that the BCL System consistently achieves clear tumor margins across a variety of cases. Notably, results published in leading surgical journals back up its effectiveness and the precision of resections achieved with the BCL System.
Pathway to U.S. Approval
At this time, Cairn Surgical is conducting a pivotal trial with 448 participants at up to 25 centers in the U.S. This research is vital for obtaining FDA approval and expanding the availability of the BCL System in the United States. The primary goal of this trial is to assess the positive margin rate while also evaluating surgical factors such as specimen volumes and operative time.
About Cairn Surgical
Cairn Surgical, Inc. is leading the charge in transforming breast cancer surgery by creating patient-tailored surgical guides using advanced imaging and 3D printing technologies. While the Breast Cancer Locator is currently available in select parts of Europe, it remains an investigational device in the U.S., limited to clinical studies.
Frequently Asked Questions
What is the Breast Cancer Locator System?
The Breast Cancer Locator (BCL™) System is an innovative tool designed to help surgeons accurately locate and remove tumors during breast-conserving surgeries.
Who conducted the first commercial operation using the BCL System?
Prof. Dr. med. Hisham Fansa, who leads the Breast Center in Switzerland, performed the first commercial procedure utilizing the BCL System.
What advantages does the BCL System offer?
The BCL System increases surgical precision, improves the chances of achieving clear margins, and may reduce the likelihood of needing additional surgeries.
How was the BCL System created?
The BCL System was developed through advanced imaging techniques paired with 3D printing, which allows for patient-specific surgical guides tailored to the unique characteristics of individual tumors.
What’s the status of the pivotal trial for the BCL System in the U.S.?
The U.S. pivotal trial is in progress, aiming to enroll 448 women to support FDA clearance and enhance access to this groundbreaking technology.
